PŘEHLEDOVÉ ČLÁNKY Přehlédnutý karcinom horní části gastrointestinálního traktu (PEUGIC) – od epidemiologie k analýze hlavních příčin E24 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék. 2023;69(8):E19-E25 / www.casopisvnitrnilekarstvi.cz V čase diagnózy endoskopista aktivně zjišťuje anamnézu od pacienta i z informačního systému, zda byla u pacienta provedena gastroskopie v posledních 3 letech a s jakým výsledkem. Pokud předchozí gastroskopie nádor nezjistila, jedná se o PEUGIC. Součástí sledování PEUGIC na každém pracovišti by měla být i analýza jednotlivých příčin vedoucích k PEUGIC. Jako návod k této analýze může sloužit systém analýzy příčin, který vytvořil Kamran a kolektiv (Schéma 1). Klíčem ke zvýšení kvality horní endoskopie v našich zemích jsou Standardy kvality České gastroenterologické společnosti pro gastroskopii, jejichž stanoviska by měla být známa všem endoskopistům a měla by být dodržována na všech endoskopických jednotkách v České republice. LITERATURA 1. Alexandre L, Tsilegeridis-Legeris T, Lam S. Clinical and Endoscopic Characteristics Associated With Post-Endoscopy Upper Gastrointestinal Cancers: A Systematic Review and Meta-analysis. Gastroenterology. 2022;162(4):1123-1135. Available from DOI: https:// doi.org/10.1053/j.gastro.2021.12.270. 2. Chen D, Fu M, Chi L. Prognostic and predictive value of a pathomics signature in gastric cancer. Nat Commun. 2022;13(1):6903. Available from DOI: https://doi.org/10.1038/ s41467-022-34703-w. 3. Liu ChQ, Ma YL, Qin Q. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 2023;14(1):3-11. Available from DOI: https://doi.org/10.1111%2F1759-7714.14745. 4. Novotvary 2018 ČR. Data z 2018. Ústav zdravotnických informací a statistiky ČR. [cit.2021-04-25]. Available from www: https://www.uzis.cz/res/f/008352/novotvary2018.pdf. 5. Martinek J, Trunecka P, et al. Gastroenterologie a hepatologie v algoritmech. Maxdorf: Praha 2021: 143-154. ISBN 978-80-7345-684-9. 6. Holmberg D, Santoni G, Euler-Chelpin MC, et al. Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology 2022;162(2):431-438. Available from DOI: https://doi.org/10.1053/j. gastro.2021.10.003. 7. Goetz N, Lamba M, Ryan K, et al. Post-Endoscopy Upper Gastrointestinal Cancer Rate in a Tertiary Referral Centre: An Australian Data Linkage Analysis. J Gastrointest Cancer 2022; online ahead of print. Available from https://doi.org/10.1007/s12029-022-00874-4. 8. Menon S, Trudgill N. How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis. Endosc Int Open 2014; 2(2): e46-e50. Available from DOI: https://doi.org/10.1055%2Fs-0034-1365524. 9. Chadwick G, Groene O, Hoare J, et al. A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy. Endoscopy. 2014;46 (7):553-560. Available from DOI: https://doi.org/10.1055/s-0034-1365646. 10. Chadwick G, Groene O, Riley S, et al. Gastric cancers missed during endoscopy in England. Clin Gastroenterol Hepatol. 2015;13(7):1264-1270. Available from DOI: https:// doi.org/10.1016/j.cgh.2015.01.025. 11. Pimenta-Melo AR, Monteiro-Soares M, Libânio D, et al. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(9):1041-1049. Available from DOI: https://doi. org/10.1097/meg.0000000000000657. 12. Cheung D, Menon S, Hoare J, et al. Factors associated with upper gastrointestinal cancer occurrence after endoscopy that did not diagnose cancer. Dig Dis Sci. 2016;61(9):26742684. Available from DOI: https://doi.org/10.1007/s10620-016-4176-4. 13. Kamran U, King D, Abbasi A, et al. A root cause analysis system to establish the most plausible explanation for post-endoscopy upper gastrointestinal cancer. Endoscopy. 2023; 55(2):109-118. Available from DOI: https://doi.org/10.1055/a-1917-0192. 14. Januszewicz W, Witczak K, Wieszczy P, et al. Prevalence and risk factors of upper gastrointestinal cancers missed during endoscopy: a nationwide registry-based study. Endoscopy. 2022;54(7):653-660. Available from DOI: https://doi.org/10.1055/a-1675-4136. 15. Beg S, Ragunat K, Wyman A, Banks M, Trudgill N, Pritchard D, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut. 2017;66(11):1886-1899. Available from DOI: https:// doi.org/10.1136/gutjnl-2017-314109. 16. Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2016;48(9):843-864. Available from DOI: http://dx.doi.org/10.1055/s-0042-113128. 17. Januszewicz W, Kaminski MF. Quality indicators in diagnostic upper gastrointestinal endoscopy. Therapeutic Advances in Gastroenterology. 2020;13:1-19. Available from DOI: https://doi.org/10.1177%2F1756284820916693. 18. Cyrany J, Balihar K, Falt P, et al. Gastroskopie – standardy kvality České gastroenterologické společnosti ČLS JEP. Gastroent Hepatol. 2022;76(3):194-211. Dostupné z DOI: https://doi.org/10.48095/ccgh2022194. 19. Fujita S. Biology of early gastric carcinoma. Pathol Res Pract. 1978;163 (4):297-309. Available from DOI: https://doi.org/10.1016/s0344-0338(78)80028-4. 20. Yalamarthi S, Witherspoon P, McCole D, et al. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy. 2004;36(10):874-879. Available from DOI: https://doi.org/10.1055/s-2004-825853. 21. Stepan M, Falt P, Pipek B, et al. Administration of mucolytic solution before upper endoscopy – double-blind, monocentric, randomized study. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic. 2023;167(1):69-73. Available from DOI: https://doi.org/10.5507/bp.2021.038. 22. Elvas L, Areia M, Brito D, Alves S, Saraiva S, Cadime AT. Premedication with simethicone and N-acetylcysteine in improving visibility during upper endoscopy: a double- -blind randomized trial. Endoscopy. 2017;49(2):139-145. Available from DOI: http://dx. doi.org/10.1055/s-0042-119034. 23. Stepan M, Fojtik P, Falt P, et al. Administration of maximum dose of mucolytic solution before upper endoscopy-a double-blind, randomized trial. Eur J Gastroenterol Hepatol. 2023;35(6):635-640. Available from DOI: https://doi.org/10.1097/meg.0000000000002559. 24. Manfredi G, Berte R, Liritano E, et al. Premedication with simethicone and N-acetylcysteine for improving mucosal visibility during upper gastrointestinal endoscopy in a Western population. Endosc Int Open. 2021; 09(02): E190-E194. Available from DOI: https://doi.org/10.1055/a-1315-0114. 25. Wang YR, Loftus EV, Judge TA, et al. Rate and predictors of interval esophageal and gastric cancers after esophagogastroduodenoscopy in the United States. Digestion. 2016; 94(3):176-180. Available from DOI: https://doi.org/10.1159/000452794. 26. Hernanz N, Rodriguez de Santiago E, Marcos Prieto HM et al. Characteristics and consequences of missed gastric cancer: a multicentric cohort study. Dig Liver Dis. 2019; 51(6): 894-900. Dostupné z DOI: https://doi.org/10.1016/j.dld.2019.02.006. 27. Rodriguez de Santiago E, Hernanz N, Marcos-Prieto HM, et al. Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study. United European Gastroenterol J. 2019;7(2):189-198. Available from DOI: https://doi. org/10.1177/2050640618811477. 28. Rutter MD, Beintaris I, Valori R, et al. World Endoscopy Organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology 2018;155(3):909-925. Available from DOI: https://doi.org/10.1053/j.gastro.2018.05.038. 29. Jin S, Jeon SW, Kwon Y, et al. Optimal endoscopic screening interval for early detection of gastric cancer: a single-center study. J Korean Med Sci. 2018;33(23):e166. Available from DOI: https://doi.org/10.3346%2Fjkms.2018.33.e166. 30. Cho YS, Chung IK, Kim JH, et al. Risk factors of developing interval early gastric cancer after negative endoscopy. Dig Dis Sci. 2015;60(4):936-43. Available from DOI: https://doi.org/10.1007/s10620-014-3384-z. 31. Beck M, Bringeland EA, Qvigstad G, et al. Gastric Cancers Missed at Upper Endoscopy in Central Norway 2007 to 2016—A Population-Based Study. Cancers. 2021,13(22): 5628. Available from DOI: https://doi.org/10.3390/cancers13225628. 32. PGD Guillena, VJM Alvarado, MJ Ramiro, et al. Gastric cancer missed at esophagogastroduodenoscopy in a well-defined Spanish population. Dig Liver Dis. 2019;51(8):11231129. Available from DOI: https://doi.org/10.1016/j.dld.2019.03.005. 33. Gavric A, Hanzel J, Zagar T, et al. Survival outcomes and rate of missed upper gastrointestinal cancers at routine endoscopy: a single centre retrospective cohort study. Eur J Gastroenterol Hepatol. 2020;32(10):1312-1321. Available from DOI: https://doi. org/10.1097/MEG.0000000000001863. 34. Januszewicz W, Wieszczy P, Bialek A, et al. Endoscopist biopsy rate as a quality indicator for outpatient gastroscopy: a multicenter cohort study with validation. Gastrointest Endosc. 2019;89(6):1141-1149. Available from DOI: https://doi.org/10.1016/j.gie.2019.01.008. 35. Tai F.W.D, Wray N, Sidhu R, et al. Factors associated with oesophagogastric cancers missed by gastroscopy: a case–control study. Frontline Gastroenterol. 2019;11:194-201. Available from DOI: http://dx.doi.org/10.1136/flgastro-2019-101217. 36. van Putten M, Johnston BT, Murray LJ, et al. Missed‘ oesophageal adenocarcinoma and high-grade dysplasia in Barrett‘s oesophagus patients: a large population-based study. United European Gastroenterol J. 2018;6 (4):519-528. Available from DOI: https:// doi.org/10.1177/2050640617737466.
RkJQdWJsaXNoZXIy NDA4Mjc=